- Autor
- Organizace
-
Pracoviště
3rd Medical Department with Haematolo... 1 Breast Center Department of Gynecolog... 1 Cancer Cluster Salzburg Salzburg Austria 1 Centro de Medicina Subaquática e Hipe... 1 Department for Haemato Oncology LKH H... 1 Department of Internal Medicine and M... 1 Department of Medical Oncology Hospit... 1 Department of Medical Oncology Instit... 1 Department of Medical Oncology The Ne... 1 Department of Medicine 1 Division of ... 1 Department of Obstetrics and Gynecolo... 1 Dipartimento di Oncologia Ospedale Sa... 1 Département d'oncologie médicale Cent... 1 Faculdade de Medicina Universidade do... 1 Faculty of Medicine in Pilsen Charles... 1 Haematology and Oncology Department C... 1 Institute of Computer Science Czech A... 1 Internal Medicine 1 for Hematology wi... 1 Medical Oncology Department Hospital ... 1 Medical Oncology Department U O C Cli... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
- Organizace
-
Pracoviště
3rd Medical Department with Haematolo... 1 Breast Center Department of Gynecolog... 1 Cancer Cluster Salzburg Salzburg Austria 1 Centro de Medicina Subaquática e Hipe... 1 Department for Haemato Oncology LKH H... 1 Department of Internal Medicine and M... 1 Department of Medical Oncology Hospit... 1 Department of Medical Oncology Instit... 1 Department of Medical Oncology The Ne... 1 Department of Medicine 1 Division of ... 1 Department of Obstetrics and Gynecolo... 1 Dipartimento di Oncologia Ospedale Sa... 1 Département d'oncologie médicale Cent... 1 Faculdade de Medicina Universidade do... 1 Faculty of Medicine in Pilsen Charles... 1 Haematology and Oncology Department C... 1 Institute of Computer Science Czech A... 1 Internal Medicine 1 for Hematology wi... 1 Medical Oncology Department Hospital ... 1 Medical Oncology Department U O C Cli... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Gampenrieder, S P
Autor Gampenrieder, S P Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria Cancer Cluster Salzburg, Salzburg, Austria IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria
- Dezentjé, V
- Lambertini, M
- de Nonneville, A
- Marhold, M
- Le Du, F
- Cortés Salgado, A
- Alpuim Costa, D
- Vaz Batista, M
- Chic Ruché, N
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 2016-01-01
Elsevier Open Access Journals
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
PubMed
36563519
DOI
10.1016/j.esmoop.2022.100747
Knihovny.cz E-zdroje
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
- MeSH
- lidé MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- triple-negativní karcinom prsu * farmakoterapie metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.